Interactions between drugs and asian medicine: Displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicines Chan Su and Lu-Shen-Wan

Therapeutic Drug Monitoring

Volumn 22, Issue 2, 2000, Pages 155-159

  Datta, Pradip ^a   Dasgupta, Amitava ^b  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bufalin; Digitoxin; Free digitoxin

Indexed keywords

BUFALIN; CHINESE DRUG; DIGITOXIN; LU SHEN WAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; BINDING SITE; CHAN SU; CHEMOLUMINESCENCE; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; PRIORITY JOURNAL;

BINDING SITES; BUFANOLIDES; CARDIOTONIC AGENTS; DIGOXIN; DRUG INTERACTIONS; HUMANS; MATERIA MEDICA; PROTEIN BINDING;

EID: 0034037813     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200004000-00002     Document Type: Article

References (16)

1. Koren G, Soldin SJ. Cardiac glycosides. Clin Lab Med 1987;7: 587-606.
2. Stone JA, Soldin SJ. An update on digoxin. Clin Chem 1989;35: 1326-31.
3. Datta P, Konh D, Leonard H. An automated chemiluminescent immunoassay for digitoxin. Ther Drug Monit 1995;17:394.
4. Filer J, Edward MW, Daly JW, Myers CW. Widespread occurrence in frogs and toad skins of skin compounds interacting with ouabin site for Na, K-ATPase. Science 1980;208:505-6.
5. Barry TL, Petzinger G, Zito W. GC/MS comparison of the West Indian aphrodisiac "Love Stone" to Chinese medicine Chan Su. Bufotenine and related bufadienolides. J Forensic Sci 1996;41: 1068073.
6. Panesar NS. Bufalin and unidentified substances in traditional Chinese medicine cross react in commercial digoxin assay. Clin Chem 1992;38:2155-6.
7. Chern MS, Ray CY, Wu D. Biological intoxication to digitalis like substances after ingestion of cooked toad soup. Am J Cardiol 1991; 67:443-4.
8. Barre J, Didney F, Delion F, Tillemont JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988;10:133-43.
9. Scheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentration of drugs. In Melmon KL, Morrelli HF, eds. Clinical pharmacology: basic principles of therapeutics. New York: Macmillan; 1978:71-109.
10. Argyl JC, Kinniburg DW, Costa R. Evaluation of an ultrafiltration-fluorescence polarization immunoassay for monitoring unbound phenytoin. Ther Drug Monit 1984;6:117-20.
11. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effect. Clin Pharmacol Ther 1982;31:642-9.
12. Fraser DG, Ludden TM, Evans RP, Sutherland EW. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther 1980;27:165-9.
13. Leonard RF, Rankin GO, Robinson DS, Melnic DE. Phenytoin-salicylate interactions. Clin Pharmacol Ther 1981;29:56-60.
14. Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolemtin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit 1996;18:97-99.
15. Dasgupta A, Emerson L. Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: Lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit 1996:18: 654-59.
16. Dasgupta A, Volk A. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitors in uremic serum that blocks valproic acid-naproxen interactions. Ther Drug Monit 1996;18:284-287.